| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T276 |
0-26 |
Sentence |
denotes |
Clinical Research on LHQWC |
| T277 |
27-208 |
Sentence |
denotes |
Modern clinical studies have shown that LHQWC has therapeutic effects against viral diseases, such as COVID-19, SARS, MERS, influenza, and human infection with H7N9 avian influenza. |
| T278 |
209-325 |
Sentence |
denotes |
It can also be used to treat URI, chronic obstructive pulmonary disease (COPD) and other conditions (see Table 3 ). |
| T279 |
326-1049 |
Sentence |
denotes |
LHQWC has been recommended in diagnosis and treatment schemes such as China’s SARS Diagnosis and Treatment Scheme (Version 2004) (Chinese Medical Association and China Association of Chinese Medicine, 2004), MERS Diagnosis and Treatment Scheme (Version 2015) (National Health and Family Planning Commission of People’s Republic of China, 2015), China’s Influenza Diagnosis and Treatment Scheme (Version 2019) (National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine, 2019), and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017) (National Health and Family Planning Commission of People's Republic of China, 2017). |
| T280 |
1050-1186 |
Sentence |
denotes |
Ke Hu et al. conducted a prospective multicenter open-label randomized controlled trial on LHQWC capsule in confirmed cases of COVID-19. |
| T281 |
1187-1331 |
Sentence |
denotes |
Patients (284) were randomized to receive usual treatment alone or in combination with LHQWC capsules (four capsules, thrice daily) for 14 days. |
| T282 |
1332-1413 |
Sentence |
denotes |
The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. |
| T283 |
1414-1550 |
Sentence |
denotes |
The recovery rate was significantly higher in the combined treatment group compared with the control group (91.5% vs. 82.4%, p = 0.022). |
| T284 |
1551-1648 |
Sentence |
denotes |
The median time to symptom recovery was markedly shorter in the combined treatment group (median: |
| T285 |
1649-1675 |
Sentence |
denotes |
7 vs. 10 days, p < 0.001). |
| T286 |
1676-1849 |
Sentence |
denotes |
Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in the combined treatment group (all p < 0.001). |
| T287 |
1850-2044 |
Sentence |
denotes |
The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p < 0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) were also higher in the combined treatment group. |
| T288 |
2045-2161 |
Sentence |
denotes |
However, the two groups did not differ in the rate of conversion to severe cases or viral assay findings (p > 0.05). |
| T289 |
2162-2220 |
Sentence |
denotes |
No serious adverse events were reported (Hu et al., 2020). |
| T290 |
2221-2426 |
Sentence |
denotes |
Ruibing Lyu et al. conducted clinical research on 63 patients receiving conventional therapy in combination with LHQWC (treatment group) and 38 patients receiving only conventional therapy (control group). |
| T291 |
2427-2484 |
Sentence |
denotes |
Clinical data were collected 10 days after the treatment. |
| T292 |
2485-2699 |
Sentence |
denotes |
A comparison between the two groups was performed in terms of disappearance rates of cardinal symptoms (fever, cough, and weakness), duration of fever and disappearance rates of other individual symptoms and signs. |
| T293 |
2700-2907 |
Sentence |
denotes |
The disappearance rates of fever, cough, and weakness in the treatment group were 86.7%, 55.6%, and 82.5%, respectively, which were higher than those in the control group (67.7%, 30.6%, and 58.6%; p < 0.05). |
| T294 |
2908-3015 |
Sentence |
denotes |
The median duration of fever was 6 days in patients in the treatment group and 7 days in the control group. |
| T295 |
3016-3097 |
Sentence |
denotes |
There was no statistically significant difference between the groups (p = 0.171). |
| T296 |
3098-3247 |
Sentence |
denotes |
The disappearance rates of short breath and moist crackles (68.2% and 56.0%) were higher than those in the control group (20.0% and 20.0%, p < 0.05). |
| T297 |
3248-3415 |
Sentence |
denotes |
There were four cases of aggravation in the treatment group (6.4%) and six cases in the control group (15.8%), with no statistically significant difference (p > 0.05). |
| T298 |
3416-3498 |
Sentence |
denotes |
There were no obvious adverse reactions in the treatment group (Lyu et al., 2020). |
| T299 |
3499-3627 |
Sentence |
denotes |
Dezhong Cheng et al. conducted a multi-center retrospective analysis of the therapeutic effect of LHQWC in 51 COVID-19 patients. |
| T300 |
3628-3758 |
Sentence |
denotes |
The control group was treated with simple nutritional support, symptomatic treatment, antiviral therapy and antimicrobial therapy. |
| T301 |
3759-3881 |
Sentence |
denotes |
The treatment group was combined with LHQWC (6 g/bag) on the basis of the control group, one bag each time, 3 times a day. |
| T302 |
3882-3946 |
Sentence |
denotes |
The clinical data of patients treated for 7 days were collected. |
| T303 |
3947-4135 |
Sentence |
denotes |
The results showed that combined application of LHQWC significantly improved fever, weakness, cough, shortness of breath, chest distress, anorexia, and other clinical symptoms of COVID-19. |
| T304 |
4136-4315 |
Sentence |
denotes |
Improvements of the main symptoms and reduced incidence of the severe form suggested that LHQWC could be effective in the treatment of patients with COVID-19 (Cheng et al., 2020). |
| T305 |
4316-4440 |
Sentence |
denotes |
Ping Yu et al. conducted a study on the therapeutic effect of LHQWC combined with Abidole in the treatment of mild COVID-19. |
| T306 |
4441-4503 |
Sentence |
denotes |
A total of 295 patients were randomly divided into two groups. |
| T307 |
4504-4682 |
Sentence |
denotes |
The control group (n = 148) was treated with Abidole (0.2 g per day) orally, and the observation group (n = 147) was treated with LHQWC (6 g, thrice daily) combined with Abidole. |
| T308 |
4683-4938 |
Sentence |
denotes |
The results showed that the total effective rate of the observation group was significantly higher than that of the control group (80.95% vs 64.86%), and the rate of severe illness was significantly lower than that of the control group (14.29% vs 23.65%). |
| T309 |
4939-5327 |
Sentence |
denotes |
After 7 days of treatment, the scores for the main TCM syndromes (fever, fatigue, cough, dry throat, chest tightness) and the levels of C-reactive protein (CRP) and procalcitonin (PCT) in the observation group were significantly lower than those in the control group (p < 0.05), while white blood cells (WBC) and lymphocyte (LYM) were significantly higher than those in the control group. |
| T310 |
5328-5544 |
Sentence |
denotes |
The effective rate of chest computerized tomography (CT) in the observation group was 69.39%, which was higher than that in the control group (62.84%), but the difference was not statistically significant (p > 0.05). |
| T311 |
5545-5614 |
Sentence |
denotes |
There were no serious drug-related adverse reactions in either group. |
| T312 |
5615-5883 |
Sentence |
denotes |
The results show that LHQWC combined with Abidole can effectively relieve clinical symptoms in patients with mild COVID-19, regulate the expression of related inflammatory factors, improve the curative effect and reduce the rate of severe illness (Yu P. et al., 2020). |
| T313 |
5884-5994 |
Sentence |
denotes |
Lili Liu et al. conducted a retrospective analysis of the therapeutic effect of LHQWC in 32 COVID-19 patients. |
| T314 |
5995-6037 |
Sentence |
denotes |
The patients were divided into two groups: |
| T315 |
6038-6187 |
Sentence |
denotes |
Group A + L, in which 18 patients received Abidole (0.2 g, thrice daily) combined with LHQWC; and Group L, in which 14 patients received LHQWC alone. |
| T316 |
6188-6247 |
Sentence |
denotes |
During treatment there was one critical case in each group. |
| T317 |
6248-6353 |
Sentence |
denotes |
Abnormal liver function was observed in 14 cases (77.78%) in Group A + L and 8 cases (57.14%) in Group L. |
| T318 |
6354-6456 |
Sentence |
denotes |
Antibiotic treatment was applied in 17 cases (94.44%) in Group A + L and 13 cases (92.86%) in Group L. |
| T319 |
6457-6557 |
Sentence |
denotes |
Glucocorticoid use was reported in 10 cases (55.56%) in Group A + L and 9 cases (64.29%) in Group L. |
| T320 |
6558-6932 |
Sentence |
denotes |
Compared with Group L, significantly faster recovery of temperature (t = −2.471, p = 0.019), recovery of respiratory symptoms (t = −2.918, p = 0.007), chest CT inflammation absorption (t = −2.937, p = 0.006), time until two consecutive negative virus nucleic acid tests (t = −2.930, p = 0.006), and shorter hospital stay (t = −2.785, p = 0.009) were observed in Group A + L. |
| T321 |
6933-7066 |
Sentence |
denotes |
Abidor combined with LHQWC can be used to treat COVID-19, with good tolerance, to shorten the course of treatment (Liu et al., 2020). |
| T322 |
7067-7224 |
Sentence |
denotes |
Zhongping Duan et al. conducted a random, double-blind, and positive-drug parallel control clinical trial on the efficiency and safety of LHQWC against H1N1. |
| T323 |
7225-7303 |
Sentence |
denotes |
It was found that LHQWC reduced disease severity and the duration of symptoms. |
| T324 |
7304-7457 |
Sentence |
denotes |
The drug was also well tolerated, indicating that LHQWC might become an alternative therapeutic measure against H1N1 viral infection (Duan et al., 2011). |
| T325 |
7458-7699 |
Sentence |
denotes |
Pan Zhao et al. found by meta-analysis that LHQWC improved cough, sore throat, body ache, and other symptoms of patients infected with H1N1 virus, reduced the duration of fever, and was more effective than oseltamivir (Zhao P. et al., 2014). |
| T326 |
7700-7822 |
Sentence |
denotes |
Shiheng Wang et al. conducted a systematic review of the literature on efficacy and safety of LHQWC in treating viral flu. |
| T327 |
7823-8060 |
Sentence |
denotes |
The results showed that LHQWC gave a better total response rate, symptom improvement rate and body temperature recovery rate than the control group in treating viral flu, but consideration of its safety was important (Wang et al., 2019). |
| T328 |
8061-8351 |
Sentence |
denotes |
Li Tiehui et al. compared the clinical therapeutic effect of LHQWC and vitamin C Yinqiao Tablets in patients with URI, and found that LHQWC significantly improved nasal congestion, fever, headache, sore throat, weakness, aches in the limbs, intolerance of cold, and other clinical symptoms. |
| T329 |
8352-8437 |
Sentence |
denotes |
LHQWC had high efficacy and safety, and was therefore worthy of promotion (Li, 2019). |
| T330 |
8438-8687 |
Sentence |
denotes |
Dong Liang et al. conducted clinical research on 100 patients with COPD, and discovered that LHQWC improved conditions in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), especially those in the high risk subgroup. |
| T331 |
8688-8803 |
Sentence |
denotes |
The mode of action might be related to its ability to reduce release of inflammatory mediators (Dong et al., 2014). |
